Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-FA (1) ·
4-MeO-PCP (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Alprazolam (1) ·
Bromazolam (1) ·
Butylone (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Ephenidine (1) ·
Ephylone (1) ·
Ethylone (1) ·
Eticyclidine (1) ·
Ibogaine (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methoxetamine (1) ·
Methylone (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
PMA (1) ·
PMMA (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Xenon (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (3) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (35) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (35) ·
0.25 mg (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
None (35) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 38 results in range #1 to #38.